As of 2026-08-28, Emergent BioSolutions Inc. (EBS) trades at $5.94 against an EvidInvest fair-value range of $-11.99–$36.50 (base estimate $18.02), built from 4 independent valuation methods on filed financial statements. The market price is 67% below the base estimate, so the models read the stock as fairly valued. Research, not investment advice.
Download the full EBS valuation report (PDF) — free
DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.
PEG Ratio is not meaningful: Insufficient price/EPS data
Interpretation
PEG = P/E ÷ Annual EPS Growth Rate (%). Peter Lynch's growth-adjusted value metric.
Interpretation
EV/EBITDA = Enterprise Value ÷ EBITDA. Capital-structure neutral — preferred by professional investors.
Interpretation
P/S = Market Cap ÷ Revenue. Useful for growth/unprofitable companies. SaaS/high-growth norms higher.
Interpretation
P/B = Price ÷ Book Value per Share. Essential for banks, REITs, and asset-heavy companies.
60.3% discount vs current price
Interpretation
√(22.5 × EPS × Book Value/Share) — Benjamin Graham's intrinsic value estimate.
-53.6% vs current price ($5.94)
🔴 Destroying value
Greenwald EPV assumes zero future growth — this is the floor value of the business as a going concern.